Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.
Sorafenib
immunotherapy
nivolumab
renal cell carcinoma
skin disorder
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
27
05
2021
revised:
19
06
2021
accepted:
22
06
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab. Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids. When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders.
Sections du résumé
BACKGROUND
BACKGROUND
We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab.
CASE REPORT
METHODS
Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids.
CONCLUSION
CONCLUSIONS
When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders.
Identifiants
pubmed: 34410996
pii: 35/5/2969
doi: 10.21873/invivo.12591
pmc: PMC8408725
doi:
Substances chimiques
Antineoplastic Agents
0
Phenylurea Compounds
0
Niacinamide
25X51I8RD4
Nivolumab
31YO63LBSN
Sorafenib
9ZOQ3TZI87
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2969-2974Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Jpn J Clin Oncol. 2015 Oct;45(10):953-62
pubmed: 26206897
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Dermatol Sci. 2017 Dec;88(3):308-319
pubmed: 28843624
Mol Clin Oncol. 2017 Sep;7(3):383-385
pubmed: 28808573
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282824
Allergol Int. 2013 Mar;62(1):99-104
pubmed: 23267208
Cancer Immunol Res. 2013 Dec;1(6):373-7
pubmed: 24490176
Invest New Drugs. 2017 Feb;35(1):105-107
pubmed: 27599705
Eur J Cancer. 2019 Jun;114:67-75
pubmed: 31075726
N Engl J Med. 2012 Mar 1;366(9):866-8
pubmed: 22375995